title: Haemophilus influenzae type b vaccine in India: need and timing, immunogenecity and tolerance.
abstract: OBJECTIVE
  (i) To assess the natural immunity and susceptibility to Haemophilus influenzae type b (Hib) infections in children in India. (ii) To study the immunogenecity and tolerance of Hib vaccine (ACTHIB) in young infants.
  
  
  METHODS
  (i) Cross sectional study. (ii) Prospective trial.
  
  
  METHODS
  Well baby and immunization clinics.
  
  
  METHODS
  (i) PRP antibody titers against Hib estimated in 172 healthy infants and children aged 1 month to 10 years. (ii) Antibody titres estimated before and after ACTHIB vaccine given with primary immunization (age group 6 to 8 weeks) in 50 babies.
  
  
  RESULTS
  (i) Naturally protective levels of Hib antibodies found in less than 20% of infants under one year, but in over 80% above 4 years. (ii) Seroconversion after ACTHIB vaccination was 100% with very high protective levels. There were no significant adverse reactions.
  
  
  CONCLUSIONS
  ACTHIB vaccine proved to be safe and highly immunogenic. As susceptibility to Hib is highest in the first year of life, the vaccine should be recommended in the primary immunization schedule (combined with DPT). The very high titers achieved suggest the possibility of decreasing the number of doses or the amount of antigen to reduce the prevalent high cost.
authors.affiliation: Department of Pediatrics, K.E.M. Hospital, Pune.
authors.forename: D
authors.initials: D
authors.lastname: Acharya
authors.forename: S
authors.initials: S
authors.lastname: Bhave
authors.forename: V
authors.initials: V
authors.lastname: Joshi
authors.forename: A
authors.initials: A
authors.lastname: Bavdekar
authors.forename: A
authors.initials: A
authors.lastname: Pandit
mesh_terms: D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage*; D005260:Female; D006192:Haemophilus Infections / Q000276:immunology* / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007113:Immunity, Innate; D007115:Immunization Schedule; D007194:India; D007223:Infant; D008297:Male; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D017778:Vaccines, Combined